Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)

Next Previous
Trial Profile

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Bortezomib (Primary) ; Busulfan (Primary) ; Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Maraviroc (Primary) ; Mesna (Primary) ; Pentostatin (Primary) ; Plerixafor (Primary) ; Prednisone (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; B-cell prolymphocytic leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell prolymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 29 Oct 2024 Status changed from suspended to recruiting.
  • 08 Dec 2023 Status changed from recruiting to suspended.
  • 30 Jan 2023 Planned initiation date (estimated date for recruitment of the first subject) changed to 5 Feb 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top